A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in
adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital Queen Elizabeth II Health Sciences Centre